Tuesday, 07 Apr 2020

You are here

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.

Chen and colleagues reported in Arthritis Care & Research on a propensity score-matched cohort study analyzing 11,248 matched RA patients starting abatacept or TNFi and followed until their first event.  The primary outcome was that of hospitalized (serious) infection.

Hospitalized infection was observed 37 SIE ABA treated patients compared to an event rate of 47 SIE in TNFi treated patients (HR 0.78; 95% CI 0.64-0.95).  Amongst all hospitalizable infections, the ABA associated risk was primarily significant for pulmonary related infections.

Thus, the initial use of ABA was associated with a 22% less risk for hospitalzed infections when compared to those who initiated a TNFi. The signficance was largely against those who initiated infliximab and was not significantly different when compared to those initiating etanercept or adalimumab.

In another study published in Rheumatology, Montastruc et al. assessed the risk of cancer when choosing abatacept or other biological DMARDs (bDMARD) as the initial biologic in treating RA. They also used a US commercial claims dataset with supplemental US Medicare data 2007 to 2014. (Citation source: https://buff.ly/2TCFg1b)

The  comparison included cohorts of 4328 ABA patients and 59,860 on other bDMARDs. The incidence rates for any cancer were:

  • ABA: 4.76 per 100 per year
  • bDMARDs: 3.41 per 100 per year

Abatacept had a small but significant increased risk of all cancer (aHR 1.17; 95% CI 1.06, 1.30).  These results were largely driven by a significantly increased incidence of non-melanoma skin cancer (aHR 1.20; 95% CI 1.03, 1.39).

The risk of other specific cancer sites were not significant between groups.

These findings have limitations and will need to be studied and replicated in other populations to be clinically meaningful.  

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

ACR Infusion Guidance During COVID-19 Crisis

The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.

Infusions in the Time of Coronavirus

As they say, necessity is the mother of invention. After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week. One of the few good things to come out of this crisis is that we may learn that in-person visits are not as critical as we thought, which may in turn help our specialty’s access issues.

Earlier Anakinra Initiation Warranted in Still's Disease

An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK). 

A total of 141 AOSD patients were retrospectively studied.

Overall, they found no differences in efficacy if ANK was started within 6 (or 12 mos) vs. thereafter.  

Switching Biologics in JIA

While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era. A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.